Glioma antigen

Advances in Experimental Medicine and Biology

Volumn 746, Issue , 2012, Pages 77-84

  Toda, Masahiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD133 ANTIGEN; COMPLEMENTARY DNA; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 3; GLIOMA ANTIGEN; GLIOMA EXPRESSED ANTIGEN 2; GLYCOPROTEIN GP 100; INTERLEUKIN 4; MELANOMA ANTIGEN 10; MOUSE ID ASSOCIATED PROTEIN 1; NESTIN; PHD FINGER PROTEIN 3; RECOMBINANT GAMMA INTERFERON; TENASCIN; TRANSCRIPTION FACTOR SOX6; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CYTOTOXIC T LYMPHOCYTE; DNA LIBRARY; GENE EXPRESSION; GENETIC SCREENING; GLIOMA; HUMAN; MOLECULAR CLONING; NEURAL STEM CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; SEROLOGICAL IDENTIFICATION OF ANTIGEN BY RECOMBINANT COMPLEMENTARY DNA EXPRESSION CLONING; TUMOR REJECTION;

ANTIGENS, NEOPLASM; BRAIN NEOPLASMS; CANCER VACCINES; GLIOMA; HLA ANTIGENS; HUMANS; IMMUNOTHERAPY; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84862995992     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4614-3146-6_6     Document Type: Article

References (44)

1. Dudley ME, Rosenberg SA. Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev 2003; 3:666-675. (Pubitemid 37328821)
2. Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 1999; 10:281-287. (Pubitemid 29165283)
3. Rosenberg SA. Progress in human tumour immunology and immunotherapy. Nature 2001; 411:380-384. (Pubitemid 32467048)
4. Pfeiffer P, Qvortrup C, Eriksen JG. Current role of antibody therapy in patients with metastatic colorectal cancer. Oncogene 2007; 26:3661-3678. (Pubitemid 46842711)
5. Bernard-Marty C, Lebrun F, Awada A et al. Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions. Drugs 2006; 66:1577-1591. (Pubitemid 44373744)
6. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotech 2005; 23:1147-1157. (Pubitemid 41486396)
7. Kawakami Y, Rosenberg SA. Human tumor antigens recognized by T-cells. Immunol Res 1997; 16:313-339. (Pubitemid 28026418)
8. Cox AL, Skipper J, Chen Y et al. Identification of a peptide recognized by five melanoma-specific human cytotoxic T-cell lines. Science 1994 Apr 29;264(5159):716-719. (Pubitemid 24185883)
9. Hogan KT, Eisinger DP, Cupp SB, 3rd et al. The peptide recognized by HLA-A68.2-restricted, squamous cell carcinoma of the lung-specific cytotoxic T-lymphocytes is derived from a mutated elongation factor 2 gene. Cancer Res1998; 58:5144-5150. (Pubitemid 28521175)
10. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T-lymphocytes on a human melanoma. J Immunol 2007 Mar 1;178(5):2617-2621.
11. Iizuka Y, Kojima H, Kobata T et al. Identification of a glioma antigen, GARC-1, using cytotoxic T-lymphocytes induced by HSV cancer vaccine. Int J Cancer 2006; 118:942-949. (Pubitemid 43157669)
12. Sahin U, Tureci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997; 9:709-716. (Pubitemid 27485301)
13. Chen YT, Scanlan MJ, Sahin U et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA 1997; 94:1914-1918. (Pubitemid 27113936)
14. Ueda R, Iizuka Y, Yoshida K et al. Identification of a human glioma antigen, SOX6, recognized by patients sera. Oncogene 2004; 23:1420-1427. (Pubitemid 38406837)
15. Sahin U, Tureci O, Schmitt H et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810-11813. (Pubitemid 26014201)
16. Fischer U, Struss AK, Hemmer D et al. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol 2001; 126:206-213. (Pubitemid 32995133)
17. Struss AK, Romeike BF, Munnia A et al. PHF3-specific antibody responses in over 60% of patients with glioblastoma multiforme. Oncogene 2001; 20:4107-4114. (Pubitemid 32762185)
18. Okada H, Attanucci J, Giezeman-Smits KM et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res 2001; 61:2625-2631. (Pubitemid 32685848)
19. Ueda R, Kinoshita E, Ito R et al. Induction of protective and therapeutic antitumor immunity by a DNA vaccine with a glioma antigen, SOX6. Int J Cancer 2008; 122:2274-2279. (Pubitemid 351542331)
20. Kuramoto T. Detection of MAGE-1 tumor antigen in brain tumor. Kurume Med J 1997; 44:43-51. (Pubitemid 127510158)
21. Ueda R, Yoshida K, Kawakami Y et al. Expression of a transcriptional factor, SOX6, in human gliomas. Brain Tumor Pathol 2004; 21:35-38. (Pubitemid 38915181)
22. Chi DD, Merchant RE, Rand R et al. Molecular detection of tumor-associated antigens shared by human cutaneous melanomas and gliomas. Am J Pathol 1997; 150:2143-2152. (Pubitemid 27233085)
23. Liu G, Ying H, Zeng G et al. HER-2, gp100 and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T-cells. Cancer Res 2004; 64:4980-4986. (Pubitemid 38924546)
24. Heimberger AB, Crotty LE, Archer GE et al. Epidermal growth factor receptor VIII peptide vaccination is efficacious against established intracerebral tumors. Clin Cancer Res 2003; 9:4247-4254. (Pubitemid 37204046)
25. Okano F, Storkus WJ, Chambers WH et al. Identification of a novel HLA-A*0201-restricted, cytotoxic T-lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. Clin Cancer Res 2002; 8:2851-2855. (Pubitemid 35025729)
26. Hatano M, Eguchi J, Tatsumi T et al. EphA2 as a glioma-associated antigen: a novel target for glioma vaccines. Neoplasia 2005 Aug;7(8):717-722.
27. Jin M, Komohara Y, Shichijo S et al. Identification of EphB6 variant-derived epitope peptides recognized by cytotoxic T-lymphocytes from HLA-A24 malignant glioma patients. Oncol Rep 2008; 19:1277-1283.
28. Liu G, Yu JS, Zeng G et al. AIM-2: a novel tumor antigen is expressed and presented by human glioma cells. J Immunother 2004; 27:220-226. (Pubitemid 39118086)
29. Hashiba T, Izumoto S, Kagawa N et al. Expression of WT1 protein and correlation with cellular proliferation in glial tumors. Neurol Med Chir 2007; 47:165-170; discussion 170. (Pubitemid 46663616)
30. Nonaka Y, Tsuda N, Shichijo S et al. Recognition of ADP-ribosylation factor 4-like by HLA-A2-restricted and tumor-reactive cytotoxic T-lymphocytes from patients with brain tumors. Tissue Antigens 2002; 60:319-327. (Pubitemid 36020804)
31. Murayama K, Kobayashi T, Imaizumi T et al. Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T-lymphocytes by its peptides. J Immunother 2000; 23:511-518.
32. Schmitz M, Wehner R, Stevanovic S et al. Identification of a naturally processed T-cell epitope derived from the glioma-associated protein SOX11. Cancer Lett 2007; 245:331-336. (Pubitemid 44959365)
33. Harada M, Ishihara Y, Itoh K et al. Kinesin superfamily protein-derived peptides with the ability to induce glioma-reactive cytotoxic T-lymphocytes in human leukocyte antigen-A24 glioma patients. Oncol Rep 2007; 17:629-636.
34. Izumoto S, Tsuboi A, Oka Y et al. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme. J Neurosurg 2008; 108:963-971. (Pubitemid 351656845)
35. Yajima N, Yamanaka R, Mine T et al. Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin Cancer Res 2005; 11:5900-5911. (Pubitemid 41170319)
36. Toda M. Cancer vaccine for brain tumors and brain tumor antigens. Cancer Therapy 2004; 2:21-26.
37. Zalutsky MR, Moseley RP, Benjamin JC et al. Monoclonal antibody and F(ab)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res 1990; 50:4105-4110. (Pubitemid 20225638)
38. Wikstrand CJ, Hale LP, Batra SK et al. Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. Cancer Res 1995; 55:3140-3148.
39. Reardon DA, Zalutsky MR, Bigner DD. Antitenascin-C monoclonal antibody radioimmunotherapy for malignant glioma patients. Expert Rev of Anticancer Ther 2007; 7:675-687. (Pubitemid 46805563)
40. Wikstrand CJ, Cole VR, Crotty LE et al. Generation of anti-idiotypic reagents in the EGFRvIII tumor-associated antigen system. Cancer Immunol Immunother 2002; 50:639-652. (Pubitemid 34146569)
41. Woodward WA, Sulman EP. Cancer stem cells: markers or biomarkers? Cancer Metastasis Rev 2008; 27:459-470.
42. Toda M, Iizuka Y, Yu W et al. Expression of the neural RNA-binding protein Musashi1 in human gliomas. Glia 2001; 34:1-7. (Pubitemid 32329026)
43. Tohyama T, Lee VM, Rorke LB et al. Nestin expression in embryonic human neuroepithelium and in human neuroepithelial tumor cells. Lab Investi 1992; 66:303-313.
44. Kreisl TN, Kim L, Moore K et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 2009; 27:740-745.